after reading thru, I saw some real negatives in the report as well
Revenues for the third quarter of 2013 were $181,000, compared to $636,000 for the comparable 2012 period. Revenues for the first nine months of 2013 were $1.1 million, compared to $2.0 million for the comparable 2012 period. The decrease in revenues for the three and nine month periods ending September 30, 2013, compared to the same periods in 2012, primarily reflects the recognition of a license payment from GE Healthcare UK, Limited in the third quarter of 2012 and termination of the company's license agreement with Asia Biotech Corporation in December 2012. The license agreement with GE Healthcare UK, Limited was transferred to Asterias Biotherapeutics, Inc. upon the closing of the divestiture of the company's stem cell assets.
Operating expenses for the 2013 third quarter and year-to-date periods also included restructuring charges of $116,000 and $1.0 million, respectively, related to the company's decisions in April 2013 to discontinue its discovery research programs and companion diagnostics program based on telomere length, as well as close its research laboratory facility and reduce its workforce
Market Data 
Markets 
AI
